[1] 于晋杰,王泉,刘海灿,等.ELOVL2和SLC11A1基因多态性与新疆地区人群结核病易感性的相关性[J].中南医学科学杂志,2023,51(4):469-474. YU J J,WANG Q,LIU H C,et al.Association of ELOVL2 and SLC11A1 gene polymorphisms with tuberculosis suscep-tibility in Xinjiang population[J].Med Sci J Cent South China,2023,51(4):469-474. [2] 白延璐,张阔,张宇,等.基于网络药理学和分子对接技术探究百合固金汤在肺结核治疗中的作用[J].解剖科学进展,2024,30(6):593-598. BAI Y L,ZHANG K,ZHANG Y,et al.Exploring the role of Baihe Gujin decoction in the treatment of tuberculosis based on network pharmacology and molecular docking technology[J].Prog Anat Sci,2024,30(6):593-598. [3] 姜雪,白云龙,马建军,等.2020—2023年吉林省利福平耐药肺结核患者诊治延迟现状及影响因素分析[J].中国防痨杂志,2025,47(4):416-424. JIANG X,BAI Y L,MA J J,et al.Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients,Jilin Province,2020-2023[J].Chin J Antituberc,2025,47(4):416-424. [4] 张卫平.内质网应激在利福平诱导的药物性肝损伤中的作用和机制研究[D].合肥:安徽医科大学,2016. [5] 李亚奇,郑志坚,张美诗,等.利福平通过NRF2/NQO1通路对小鼠肝细胞造成氧化损伤[J].海南医科大学学报,2025,31(4):248-253. LI Y Q,ZHENG Z J,ZHANG M S,et al.Oxidative damage to mouse liver cells caused by rifampicin through the NRF2/NQO1 pathway[J].J Hainan Med Univ,2025,31(4):248-253. [6] 刘红双,王晶,张园园,等.慈姑多糖激活Nrf2对异烟肼和利福平联用致肝损伤保护作用的体内外实验研究[J].中华中医药杂志,2022,37(2):1112-1117. LIU H S,WANG J,ZHANG Y Y,et al.In vivo and in vitro experimental study on the protective effect of Nrf2 activated by Sagittaria Sagittifolia polysaccharides on liver injury caused by isoniazid and rifampicin in combination[J].China J Tradit Chin Med Pharm,2022,37(2):1112-1117. [7] 黄伟,周新科,林铭珍,等.胃癌中新颖hsa_circ_0003071的特征、功能及预后分析[J].广州医科大学学报,2022,50(3):21-31. HUANG W,ZHOU X K,LIN M Z,et al.Characterization,function prediction and prognostic role of hsa_circ_0003071,a novel circular RNA,in gastric cancer[J].Acad J Guangzhou Med Univ,2022,50(3):21-31. [8] 许丽娜,李月,彭金咏.microRNA与药物性肝损伤[J].中国临床药理学与治疗学,2020,25(7):803-809. XU L N,LI Y,PENG J Y.microRNA and drug-induced liver injury[J].Chin J Clin Pharmacol Ther,2020,25(7):803-809. [9] XIA Q,HAN T,YANG P,et al.microRNA-28-5p regulates liver cancer stem cell expansion viaIGF-1 pathway[J].Stem Cells Int,2019,2019:8734362. [10] LI X,ZHANG H,XU L,et al.miR-15a-3p protects against isoniazid-induced liver injury via suppressing N-acetyltransferase 2 expression[J].Front Mol Biosci,2021,8:752072. [11] ZHA Z,JIA F,HU P,et al.microRNA-574-3p inhibits the malignant behavior of liver cancer cells by targeting ADAM28[J].Oncol Lett,2020,20(3):3015-3023. [12] RUPPRECHTER S A E,SLOAN D J,OOSTHUYZEN W,et al.microRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection[J].Br J Clin Pharmacol,2021,87(8):3206-3217. [13] ZHANG D D.Thirty years of NRF2:Advances and therapeutic challenges[J].Nat Rev Drug Discov,2025,24(6):421-444. [14] LV Y,YANG H,MA X,et al.Strand-specific miR-28-3p and miR-28-5p have differential effects on nasopharyngeal cancer cells proliferation,apoptosis,migration and invasion[J].Cancer Cell Int,2019,19:187. [15] HOSSEINI S F,JAVANSHIR-GIV S,SOLEIMANI H,et al.The importance of hsa-miR-28 in human malignancies[J].Biomedecine Pharmacother,2023,161:114453. [16] KALLURI R,LEBLEU V S.The biology,function,and biomedical applications of exosomes[J].Science,2020,367(6478):6977. [17] MADHUSOODANAN J.The therapeutic potential of exosomes[J].Nature,2020,581:S10-S11. |